A 2021 review notes that the effect of long-acting GLP-1 medicines on gastric emptying decreases over time, and the Zepbound and Mounjaro labels say the delay is largest after the first dose and diminishes after that.1,2,3 The effects on weight and blood sugar, by contrast, last for as long as the medicine is taken.
The stomach effect fades
The study behind the tirzepatide labels, run by the drug's maker, found that once-weekly tirzepatide delayed gastric emptying after a single dose and that the effect diminished after several doses in healthy volunteers. In people with type 2 diabetes on a rising dose, some delay remained after multiple doses.4 For semaglutide 2.4 mg, a 20-week trial measured emptying with paracetamol, a liquid-phase test, and found no evidence of slower emptying than on placebo at week 20.5
The 2021 review explains why this matters for the class. Short-acting medicines such as twice-daily exenatide keep their effect on gastric emptying during long-term treatment, while long-acting ones lose part of it. The short-acting medicines, in turn, have weaker effects on overnight and fasting blood sugar.1
Side effects follow the same curve
The most common side effects ease in a similar way. The Zepbound label says most nausea, vomiting and diarrhea happened during the dose climb and decreased over time; in its weight trials nausea was reported by 25%, 29% and 28% on 5, 10 and 15 mg, against 8% on placebo.2 The Byetta label says that nausea usually decreases over time.6 That is the reason every GLP-1 label raises the dose in steps: each step gives the body time to adjust before the next.
Weight and blood sugar do not fade
The withdrawal trials show the main effects persist. Both took people who had already been on the drug for months and split them at random: some stayed on it, and the rest were switched to placebo without knowing.
- STEP 4, semaglutide 2.4 mg. The 803 people who completed a 20-week run-in had lost 10.6% on average. Those who stayed on semaglutide kept losing weight, 7.9% more by week 68, while those switched to placebo regained 6.9%.7
- SURMOUNT-4, tirzepatide 10 or 15 mg. The 670 people who completed a 36-week lead-in had lost 20.9% on average. Those who stayed on tirzepatide lost another 5.5% by week 88, while those on placebo regained 14.0%. At week 88, 89.5% of those still on tirzepatide had kept at least 80% of the weight they lost in the lead-in, against 16.6% on placebo.8
If the weight effect wore off after months of use, the people who stayed on the drug would have drifted back toward the placebo group. They moved the other way.
A weight plateau is sometimes called tachyphylaxis, but the trials describe it differently. Weight levels off because the body's appetite feedback pushes back as weight falls, and a 2024 modelling study found that GLP-1 medicines weaken that push-back rather than losing their own effect.9 Our page on the Zepbound plateau covers it.
What it means in practice
- Fullness and nausea are strongest after starting and after each dose increase, and usually ease.
- Easing side effects do not mean the medicine has stopped working.
- The labels' warnings about a slow stomach, such as aspiration during anesthesia, still apply, because some delay can remain, as the tirzepatide study found in people with diabetes.4
Our page on nausea on a GLP-1 covers what helps in the first weeks.
Sources
- Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab 2021;46:101102. doi:10.1016/j.molmet.2020.101102
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 2, 5, 6.2, 7, 8, 12 and 17. accessdata.fda.gov
- MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 5, 6.2, 7, 8, 12 and 17. accessdata.fda.gov
- Urva S, Coskun T, Loghin C, et al. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab 2020;22:1886-1891. doi:10.1111/dom.14110
- Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23:754-762. doi:10.1111/dom.14280
- BYETTA (exenatide) injection prescribing information. AstraZeneca; DailyMed, version published September 8, 2025; highlights and section 5. dailymed.nlm.nih.gov
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA 2021;325:1414-1425. doi:10.1001/jama.2021.3224
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA 2024;331:38-48. doi:10.1001/jama.2023.24945
- Hall KD. Physiology of the weight-loss plateau in response to diet restriction, GLP-1 receptor agonism, and bariatric surgery. Obesity (Silver Spring) 2024;32:1163-1168. doi:10.1002/oby.24027
Related analyses
Nausea on a GLP-1: how common, how long, when it peaks and what helps
Ozempic and gastroparesis: what the stomach paralysis studies found
Zepbound side effects timeline: when they start, how long they last, when they ease
Zepbound plateau: when weight loss slows, why, and what the trials show
Log nausea and fullness with each dose and see how they change as weeks pass.
Open Dose Insider